Bayer to present new research findings on Xofigo (radium Ra 223 dichloride) injection at ASCO GU 2016

NewsGuard 100/100 Score

Bayer announced today that new research findings on Xofigo® (radium Ra 223 dichloride) injection will be presented at the 2016 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place January 7 – 9 in San Francisco.

"The data being presented at ASCO GU underscore Bayer's commitment to explore the full potential of radium-223 dichloride for men with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease," said Dario Mirski, M.D., Bayer's vice president and head of U.S. Medical Affairs. "The impact of advanced prostate cancer can be devastating with about 90 percent of men living with advanced prostate developing bone metastases. Our research efforts are driven by a commitment to find treatment approaches that can benefit these patients."

Among data being presented are the first safety and efficacy findings of radium-223 dichloride re-treatment in patients with metastatic castration-resistant prostate cancer and bone metastases. The safety and efficacy of radium-223 dichloride beyond six injections has not been established.

Notable studies evaluating radium-223 dichloride at ASCO GU 2016 are listed below.

Radium Ra 223 Dichloride (radium-223)

  • Radium-223 (Ra-223) re-treatment (Re-tx): First experience from an international, multicenter, prospective study in patients (Pts) with castration-resistant prostate cancer and bone metastases (mCRPC)
    • Abstract #197, Board H12, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
    • January 7, 2016 at 11:30 AM – 1:00 PM (PST)
  • Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride (Ra-223) and abiraterone acetate (AA) in men with castration-resistant prostate cancer (CRPC) patients with symptomatic bone metastases
    • Abstract #177, Board G12, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
    • January 7, 2016 at 11:30 AM – 1:00 PM (PST)
  • Phase II clinical study of radium-223 chloride (BAY 88-8223) in Japanese patients with symptomatic castration-resistant prostate cancer (CRPC) with bone metastases
    • Abstract #167, Board G2, Poster Session A: Prostate Cancer (Moscone West Building, Level 1, West Hall)
    • January 7, 2016 at 11:30 AM – 1:00 PM (PST)


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the ‘immune self,’ and how can this concept benefit immunological research?